Women are affected twice as often as men, with an estimated 40% of women above the age of 40 suffering from SUI. All existing treatment options have drawbacks that range from low and short-term efficacy (for conservative treatments) to potentially serious adverse events associated either with invasiveness or the introduction of foreign material (for more potent surgical approaches).
MUVON is developing a low-risk, minimally invasive treatment that uses the patient’s own muscle precursor cells (MPC) to regenerate the damaged sphincter muscle, thus potentially providing a cure for SUI.
Before the founding of MUVON, the team worked in the Associate project MUS.I.C. to establish and validate its GMP-compliant production process at the Wyss Zurich. This was followed by a translation into a clinical setting beginning of 2020 and the conduction of a Phase I clinical trial. With the support of Wyss Zurich the MUVON team will now proceed with the clinical and commercial development of their therapy, evaluating the efficacy of the approach during a Phase 2 clinical trial and undertaking all the required activities for a regulatory approval.
Team
Behind MUVON is a larger team of dedicated experts in their field - get to know them at www.muvon-therapeutics.com.
